Show simple item record

dc.contributor.authorChiu, Yi-Ningen_US
dc.contributor.authorLeclerc, Benoiten_US
dc.contributor.authorTownsley, Michaelen_US
dc.date.accessioned2017-06-08T12:00:41Z
dc.date.available2017-06-08T12:00:41Z
dc.date.issued2011en_US
dc.date.modified2012-05-31T22:04:38Z
dc.identifier.issn00070955en_US
dc.identifier.doi10.1093/bjc/azr005en_US
dc.identifier.urihttp://hdl.handle.net/10072/45339
dc.description.abstractDespite the growing problem of clandestine drug laboratories, there is currently little evidence of systematic knowledge regarding the crime-commission process involved in this criminal enterprise. In addition, as mentioned by Levi and Maguire, strategic measures utilized in law enforcement interventions that extend beyond immediate operational goals towards a lasting reduction in organized forms of crime are also lacking. The purpose of this study is to better understand the crime commission process of clandestine drug laboratories and identify significant points for intervention by using crime scripts. This objective is achieved through a qualitative content analysis of 25 court cases in which a crime script comprising seven stages is identified. Potential prevention measures are also underpinned and summarized according to the problem analysis triangle. It is concluded that a focus on location, chemicals and equipment might have the most detrimental effect on the overall manufacturing script process.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.languageEnglishen_US
dc.publisherOxford University Pressen_US
dc.publisher.placeUnited Kingdomen_US
dc.relation.ispartofstudentpublicationNen_US
dc.relation.ispartofpagefrom355en_US
dc.relation.ispartofpageto374en_US
dc.relation.ispartofissue2en_US
dc.relation.ispartofjournalBritish Journal of Criminologyen_US
dc.relation.ispartofvolume51en_US
dc.rights.retentionYen_US
dc.subject.fieldofresearchCauses and Prevention of Crimeen_US
dc.subject.fieldofresearchcode160201en_US
dc.titleCrime Script Analysis of Drug Manufacturing in Clandestine Laboratories Implications for Preventionen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.date.issued2011
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record